Byrne, a pediatric cardiologist and virologist, has advanced AAV vector development, helping translate gene therapy from concept to clinic — particularly for Pompe disease, Duchenne muscular dystrophy, Friedreich’s ataxia and inherited cardiomyopathies. His research has pioneered DNA delivery to muscle cells using AAVs and led to scalable clinical manufacturing methods for treatments restoring cardiac and skeletal muscle function.